An Indispensable Asset in the Treatment and Management of Bleeding and Clotting Disorders
From January 2018, Clinical and Applied Thrombosis/Hemostasis will publish all new content open access. Therefore, articles first submitted on or after 1st August 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of 1,000 USD, discounted from the full rate of 2,000 USD, is available for a limited time. Published papers will be made open access immediately with a Creative Commons licence which enables authors to retain copyright of their work and allows liberal reuse. Papers first submitted before 1st August 2017 will not be charged.
Every issue of Clinical and Applied Thrombosis/Hemostasis (CATH) addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH offers comprehensive coverage of the topics that matter most to your work, including clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders, assessment of new clinical diagnostic procedures, pharmacological agents, laboratory diagnostic procedures, and patient management plans. CATH continually evaluates new research in areas including essential drugs such as Warfarin, Heparin, low-molecular-weight Heparin, and other emerging drug therapies; the clinical impact on treatment of diseases and conditions such as diabetes, hypertension, pregnancy, hemophilia, and HIV-AIDS; factor defects; platelet disorders; fibrinolytic disorders; DNA/RNA research; and ethnic and population differences in thrombohemorrhagic disorders.
Rigorously peer-reviewed and well cited, Clinical and Applied Thrombosis/Hemostasis presents original research reports, review articles, case reports, and book/media reviews that expand your clinical perspective and help improve your clinical diagnostic skills. Some of the latest advances discussed in recent issues include
- Coagulation and Fibrinolysis in Preeclampsia and Neonates
- Differentiation of Low-Molecular-Weight Heparins: Practical Implications
- Disseminated Intravascular Coagulation Syndromes
- Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels
- Evaluation of New Japanese Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients
- Iron Deficiency and Thrombosis: Literature Review
- Oral Contraceptives and Thrombosis
- Pitfalls in Warfarin Therapy
- Platelet Function and Fibrinolytic Activity
- Prevention of Venous Thrombosis and Thrombophlebitis in Long-Haul Flights with Pycnogenol®
- Severe Thrombotic Microangiopathy and Plasmapheresis
- Spectrum of Inherited Bleeding Disorders in Indians
- Sticky Platelet Syndrome
- Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia
This journal is a member of the Committee on Publication Ethics (COPE).
Clinical and Applied Thrombosis/Hemostasis (CATH) is dedicated to serving as a forum for studies regarding the etiology, pathophysiology, clinical diagnosis, laboratory diagnosis, and treatment of thrombohemorrhagic disorders. Articles dealing with new diagnostic procedures are encouraged, provided they are clinically oriented or potentially applicable to clinical and laboratory medicine. Articles dealing with all aspects of thrombosis, hemostasis, and vascular disorders of clinical or clinical laboratory applicability are also encouraged. The contents of the journal appeal to any person interested in clinical and applied thrombohemorrhagic disorders.
From January 2018, Clinical and Applied Thrombosis/Hemostasis will publish all new content open access. Therefore, articles first submitted on or after 1st August 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of 1,000 USD, discounted from the full rate of 2,000 USD, is available for a limited time. Authors paying the APC will enjoy the benefits of immediate, full open access publishing and will utilize one of the Creative Commons licenses which enable them to retain copyright.
|William Baker, Jr. MD, FACP|
|Jawed Fareed, Ph.D||Loyola University Chicago, USA|
|Esteban Gandara||The Ottowa Hospital, General Campus, Canada|
|Deborah Hoppensteadt, Ph.D||Loyola University Chicago, USA|
|Evi Kalodiki||Ealing Hospital, UK|
|Qing Ma||New York University at Buffalo, Buffalo, NY, USA|
|Graham Pineo, M.D.||University of Calgary, Canada|
|Jeanine M. Walenga, Ph.D||Loyola University Medical Center, Maywood, IL, USA|
|Antonio Girolami, M.D.||University of Padua, Italy|
|Sylvia Haas, MD||Munich, Germany|
|Walter Jeske, Ph.D||Loyola University Medical Center, Maywood, IL, USA|
|Wolfgang Miesbach||Universitätsklinikum Frankfurt, Germany|
|Hideo Wada, M.D.||Mie University, Japan|
|Muzaffer Demir, M.D.||Trakya University, Turkey|
|Raul Altman, M.D.||Buenos Aires, Argentina|
|H. Peter Bacher, M.D., Ph.D||Long Grove, IL, USA|
|Gianni Belcaro, M.D., Ph.D||Pelcara, Italy|
|Samuel Berkman, M.D., FACP||Bevery Hills, CA, USA|
|Charles A. Carter||Pharmaceutical Strategic Initiatives, USA|
|Anthony K. Chan||McMaster University, Canada|
|Sergio Coccheri||Bologna, Italy|
|Charles J. Glueck, M.D.||Cholesterol Center, ABC Building|
|Lothar Heilmann||Russelheim, Germany|
|Joseph Heissler, Jr., Pharm.D||Pfizer Global Pharmaceuticals, USA|
|Mohammad Jamshidi, DO, FACS||Millennia Care Clinic, TX, USA|
|Valery Leytin, Ph.D||St. Michael’s Hospital, Toronto, Canada|
|Dimitri P. Mikhailidis, M.D., FRCPATH||Royal Free and University College Medical School, UK|
|Michael Mosesson, M.D.||University of Wisconsin, USA|
|Bali Netaji, M.D.||Southwest Regional Cancer Center, Australia|
|Andrew N. Nicolaides|
|William F. Pope||Dallas, TX, USA|
|Alice Runge, M.T.||Santa Monica, CA, USA|
|Arthur Sasahara, M.D.||Boston, MA, USA|
|Georg-Friedrich von Tempelhoff, M.D.||City Hospital of Ruesselshein, Germany|
|Oran Ulutin, M.D.||Istanbul, Turkey|
|David H. Van Thiel, M.D.|
|James Wilson, M.D.||Texas Medical Center, USA|
From January 2018, the Clinical and Applied Thrombosis/Hemostasis will publish all content open access. Therefore, articles first submitted on or after August 1, 2017 will be subject to an open access article process charge (APC), if accepted after peer review. An introductory APC of $1000 USD, discounted from the full rate of $2000 USD, is available for a limited time. Authors paying the APC will enjoy the benefits of immediate, full open access publishing and will utilize one of the Creative Commons licenses which enable them to retain copyright.
Accepted papers first submitted before August 1st, 2017 will not be charged.
This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the full author guidelines for Clinical and Applied Thrombosis/Hemostasis at this link, then visit the Journal’s submission site: https://mc.manuscriptcentral.com/cath to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Clinical and Applied Thrombosis/Hemostasis will be reviewed.
Clinical and Applied Thrombosis/Hemostasis will publish manuscripts submitted on or after August 1st under Creative Commons licenses. The standard license is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Clinical and Applied Thrombosis/Hemostasis editorial office as follows:
Sheila Platt, Editorial Manager